Roche CellCept labeling discussions continue following Feb. 11 approval of heart transplant indication.
Executive Summary
ROCHE CELLCEPT LABELING NEGOTIATIONS CONTINUE AFTER APPROVAL FOR HEART TRANSPLANT indication. CellCept (mycophenolate mofetil) was approved Feb. 11 for use in combination with cyclosporine and corticosteroids for the prevention of organ rejection following cardiac transplants. Roche said it would begin promoting CellCept for the new indication once labeling negotiations have been completed and after FDA has cleared its promotional materials. The company said CellCept's price would not change; the cost for a 3 g daily dose for the cardiac indication would be $19.14.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth